A Phase II/III Randomized, Multicenter Trial Comparing Sirolimus Plus Prednisone and Sirolimus/Calcineurin Inhibitor Plus Prednisone for the Treatment of Chronic Graft-versus-Host Disease (BMT CTN Protocol #0801)
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 151
- 试验地点
- 31
- 主要终点
- Proportion of Participants With Treatment Success
研究概览
简要总结
This study is designed as a combined Phase II/III, randomized, open label, multicenter, prospective comparative study of sirolimus plus prednisone versus sirolimus/calcineurin-inhibitor plus prednisone for the treatment of chronic GVHD. Patients will be stratified by transplant center and will be randomized to an experimental arm of one of the two pre-specified experimental arms (sirolimus + prednisone or the comparator arm of sirolimus + calcineurin inhibitor + prednisone) in a 1:1 ratio.
详细描述
Background: Chronic GVHD is a medical condition that can become very serious. Chronic GVHD is a common development after allogeneic transplant that occurs when the donor cells attack and damage tissues. The primary purpose of this study is to compare treatment regimens that contain sirolimus without a calcineurin inhibitor to a comparator regimen of sirolimus with a calcineurin inhibitor and evaluate how well chronic GVHD responds to treatment. The combinations of medications in this study are:
- Sirolimus + calcineurin inhibitor + prednisone
- Sirolimus + prednisone
The goal is to select a treatment regimen for further comparison in the Phase III trial.
Design Narrative: The intent is to enroll subjects at the start of initial therapy for chronic GVHD, or before their chronic GVHD is refractory to glucocorticoid therapy, or is chronically dependent upon glucocorticoid therapy and multiple secondary systemic immunosuppressive agents. Patients will be stratified by transplant center and will be randomized to one of two arms.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Suitable candidates are patients with classic chronic GVHD or overlap syndrome (classic chronic plus acute GVHD)that is: a)Previously untreated (newly diagnosed) as defined by having received < 14 days of prednisone (or equivalent) before enrollment/randomization to study therapy; b)Previously treated but inadequately responding after ≤ 16 weeks of initial therapy with prednisone and/or calcineurin inhibitor (CNI) ± additional non-sirolimus agent (started at the time of chronic GVHD diagnosis).
- •Patient or guardian willing and able to provide informed consent.
- •Stated willingness to use contraception in women of childbearing potential.
- •Stated willingness of patient to comply with study procedures and reporting requirements.
排除标准
- •Patients with late persistent acute GVHD or recurrent acute GVHD only.
- •Inability to begin prednisone therapy at a dose of greater than 0.5 mg/kg/day.
- •Receiving sirolimus for treatment of chronic GVHD (sirolimus for prophylaxis or treatment of acute GVHD is acceptable).
- •Already receiving sirolimus (for prophylaxis or treatment of acute GVHD) with prednisone at ≥ 0.25 mg/kg/day (or equivalent) ± additional agents.
- •Receiving therapy for chronic GVHD for more than 16 weeks.
- •Invasive fungal or viral infection not responding to appropriate antifungal or antiviral therapies.
- •Inadequate renal function defined as measured creatinine clearance less than 50 mL/min/1.73 m^2 based on the Cockcroft-Gault formula (adults) or Schwartz formula (age less than or equal to 12 years). Adults: estimated creatinine clearance rate (eCCr) (mL/min/) = (140 - age) x mass (kg) x (0.85 if female)/72 x serum creatinine (mg/dL; Creatinine clearance (mL/min/1.73m^2) = eCCr x 1.73/Body Surface Area (BSA) (m^2); Children: eCCr (mL/min/1.73 m^2) = k x height (cm) / serum creatinine (mg/dL) k = 0.33 (pre-term), 0.45 (full term to 1 year old), 0.55 (age 1-12 years).
- •Inability to tolerate oral medications.
- •Absolute neutrophil count less than 1500 per microliter.
- •Requirement for platelet transfusions.
- •Pregnancy (positive serum β-HCG) or breastfeeding.
- •Receiving any treatment for persistent, progressive or recurrent malignancy.
- •Progressive or recurrent malignancy defined other than by quantitative molecular assays.
- •Known hypersensitivity to sirolimus.
研究组 & 干预措施
calcineurin inhibitor
Sirolimus + calcineurin inhibitor + prednisone
干预措施: Sirolimus + calcineurin inhibitor + prednisone (Drug)
Sirolimus and prednisone
Sirolimus + prednisone
干预措施: Sirolimus + prednisone (Drug)
结局指标
主要结局
Proportion of Participants With Treatment Success
时间窗: 6 months and 24 months post-randomization
Treatment success was evaluated at 6 months in Phase II and is defined as a complete or partial response without secondary systemic immunosuppressive therapy and no recurrent malignancy or death. In Phase III, treatment success was evaluated at 24 months and is defined as a complete response without secondary systemic immunosuppressive therapy and no recurrent malignancy or death.
次要结局
- Percentage of Participants With Overall Survival(6 months and 24 months post-randomization)
- Percentage of Participants With Progression-free Survival(6 months and 24 months post-randomization)
- Percentage of Participants With Failure-free Survival(6 months and 24 months post-randomization)
- Percentage of Participants With Relapse(6 months and 24 months post-randomization)
- Percentage of Participants With Secondary Immunosuppressive Therapy Initiated(6 months and 24 months post-randomization)
- Percentage of Participants With Discontinuation of Systemic Immunosuppressive Therapy at Two Years(2 years post-randomization)
- Prednisone Dose(Baseline, 6 months, and 1 year post-randomization)
- Change in Serum Creatinine Level From Baseline(6 months and 1 year post-randomization)
- Patient-reported Chronic GVHD Severity(Baseline, 6 months, 1 year, and 2 years post-randomization)
- Provider-reported Chronic GVHD Severity(Baseline, 6 months, 1 year, and 2 years post-randomization)
- Change in Prednisone Dose From Baseline(6 months and 1 year post-randomization)
- Serum Creatinine Level(Baseline, 6 months, and 1 year post-randomization)
- SF-36 Physical Component Summary(Baseline, 2 months, 6 months, 1 year, and 2 years post-randomization)
- FACT-BMT Score(Baseline, 2 months, 6 months, 1 year, and 2 years post-randomization)
- SF-36 Mental Component Summary(Baseline, 2 months, 6 months, 1 year, and 2 years post-randomization)
- NIH Consensus Criteria Chronic GVHD Severity(Baseline, 6 months, 1 year, and 2 years post-randomization)